The conditioning process is an essential element of the ex vivo lentiviral gene therapy process, designed to enable durability and head-to-toe reach. In this expert-led session, you’ll learn about an advance in precision dosing of busulfan hailed as “a real game-changer” by Harry Malech, M.D., Chief of the Genetic Immunotherapy Section at the NIH’s NIAID, and how one company, AVROBIO, is leading the way in its goal of transforming the patient experience.
Dr. Harry Malech obtained his M.D. at Yale University, followed by clinical residency at the University of Pennsylvania and postdoctoral training at the National Cancer Institute and Yale University. He was an assistant and associate professor of Medicine at Yale University before returning to the NIH, where he has been a senior investigator since 1986. Dr. Malech is currently chairman of the NIH Institutional Biosafety Committee, which reviews all gene therapy protocols conducted at the NIH Clinical Center. He serves on the medical advisory board of the Immune Deficiency Foundation and is a clinical reviewer for the California Institute for Regenerative Medicine. Dr. Malech is an elected member of the Association of American Physicians and the American Society for Clinical Investigation. He was president of the American Society of Gene & Cell Therapy between 2014 and 2015.
Chris is a clinician-scientist with more than 25 years of cell and gene therapy experience spanning R&D, clinical medicine, bioprocessing and commercialization. He works to train the next generation of world-class scientists as professor of cell and gene therapy at University College London and reviews cutting-edge research from around the world as senior editor of the journals Cell and Gene Therapy Insights and Regenerative Medicine. Chris was instrumental in the founding of the Alliance for Regenerative Medicine (ARM), the UK-Israel Science Council and the London Regenerative Medicine Network. He’s on the scientific advisory board for several public and private companies, the UK Cell & Gene Therapy Catapult and the Canadian Centre for the Commercialization of Regenerative Medicine.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.